Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

NCT06334757 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

46

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG: Serplulimab
DRUG: Bevacizumab Biosimilar HLX04
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Henan Cancer Hospital